CTLA4 antibody (Biotin)

Catalog No. ABIN2660953

The Biotin-conjugated Hamster Monoclonal anti-CTLA4 antibody (Clone UC10-4B9) (ABIN2660953) specifically detects CTLA4 in ICFC. The antibody is reactive with Mouse samples.

Quick Overview for CTLA4 antibody (Biotin) (ABIN2660953)

Target: CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))

Reactivity: Mouse

Host: Hamster

Clonality: Monoclonal

Conjugate: This CTLA4 antibody is conjugated to Biotin

Application: Intracellular Flow Cytometry (ICFC)

Clone: UC10-4B9

Product Details anti-CTLA4 Antibody (Biotin)

Purification: The antibody was purified by affinity chromatography, and conjugated with biotin under optimal conditions. The solution is free of unconjugated biotin.

Isotype: IgG

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for CTLA4

Target: CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))

Alternative Name: CD152

Background: CD152, also known as CTLA-4 or Ly-56, is a 33 kD member of the immunoglobulin superfamily. It is expressed on activated T and B lymphocytes. CD152 is similar to CD28 in amino acid sequence, structure, and genomic organization and these two receptors share common B7 family counter-receptors (B7-1, B7-2). Whereas CD28 delivers a costimulatory signal in T cell activation, CTLA-4 negatively regulates cell-mediated immune responses. CD152 is thought to play a role in the induction and maintenance of immunological tolerance as well as the development of protective immunity and thymocyte regulation.

Pathways: Cancer Immune Checkpoints